-
公开(公告)号:US20170226095A1
公开(公告)日:2017-08-10
申请号:US15486836
申请日:2017-04-13
申请人: ABIVAX , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人: Jamal TAZI , Florence MAHUTEAU , Pierre ROUX , Romain NAJMAN , Didier SCHERRER , Carsten BROCK , Nathalie CAHUZAC , Gilles GADEA , Noelie CAMPOS , Aude GARCEL , Julien SANTO
IPC分类号: C07D413/04 , C07D217/02 , C07D401/12 , C07D403/12 , C07D215/38 , C07D241/44
CPC分类号: C07D413/04 , A61K31/4709 , A61K31/4985 , C07D213/74 , C07D215/38 , C07D215/42 , C07D215/46 , C07D217/02 , C07D241/44 , C07D401/12 , C07D403/12
摘要: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.
-
2.
公开(公告)号:US20180030078A1
公开(公告)日:2018-02-01
申请号:US15552587
申请日:2016-02-19
申请人: ABIVAX , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人: Didier SCHERRER , Aude GARCEL , Noelie CAMPOS , Jamal TAZI , Audrey VAUTRIN , Florence MAHUTEAU , Romain NAJMAN , Pauline FORNARELLI
IPC分类号: C07H17/02
CPC分类号: C07H17/02 , C07D405/12
摘要: The present invention relates to a quinoline derivative of formula (1) or one of its pharmaceutically acceptable salts. The present invention further relates to said quinoline derivative for medicament and for use in the treatment or prevention of a viral or retroviral infection and in particular AIDS or an AIDS-related condition or Human Immunodeficiency virus (HIV). The present invention also relates to a pharmaceutical composition comprising said quinoline derivative and to the process for preparing it as to a novel intermediate compound.
-
公开(公告)号:US20220127253A1
公开(公告)日:2022-04-28
申请号:US17327079
申请日:2021-05-21
申请人: ABIVAX , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人: Jamal TAZI , Florence MAHUTEAU , Pierre ROUX , Romain NAJMAN , Didier SCHERRER , Carsten BROCK , Nathalie CAHUZAC , Gilles GADEA , Noelie CAMPOS , Aude GARCEL , Julien SANTO
IPC分类号: C07D413/04 , C07D215/38 , C07D241/44 , C07D401/12 , C07D403/12 , C07D217/02 , A61K31/4709 , A61K31/4985 , C07D213/74 , C07D215/42 , C07D215/46
摘要: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.
-
4.
公开(公告)号:US20180031557A1
公开(公告)日:2018-02-01
申请号:US15552660
申请日:2016-02-19
申请人: ABIVAX , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人: Didier SCHERRER , Aude GARCEL , Noelie CAMPOS , Jamal TAZI , Audrey VAUTRIN , Florence MAHUTEAU , Romain NAJMAN , Pauline FORNARELLI
IPC分类号: G01N33/569
CPC分类号: G01N33/56983 , G01N2333/16 , G01N2469/10 , G01N2500/02 , G01N2500/10
摘要: The present invention relates to a method for screening a compound useful for treating or preventing a viral infection or a virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to promote the interaction between CBP20 and CBP80 in a sample, and b) selecting the candidate compound that is determined to promote said interaction at step a). The present invention further relates to a method for screening a compound useful for treating or preventing a viral infection or virus-related condition in an individual, comprising at least the steps of: a) determining the ability of a candidate compound to interact with CBP20 or CBP80 in a sample, and b) selecting the candidate compound that is determined to interact with CBP20 or CBP80 at step a).
-
公开(公告)号:US20180028522A1
公开(公告)日:2018-02-01
申请号:US15552921
申请日:2016-02-19
申请人: ABIVAX , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人: Didier SCHERRER , Aude GARCEL , Noelie CAMPOS , Jamal TAZI , Audrey VAUTRIN , Florence MAHUTEAU , Romain NAJMAN , Pauline FORNARELLI
IPC分类号: A61K31/47 , A61K31/706
摘要: The present invention relates to a quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim 1, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain.
-
公开(公告)号:US20140288120A1
公开(公告)日:2014-09-25
申请号:US14256334
申请日:2014-04-18
申请人: SOCIETE SPLICOS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE MONTPELLIER 2
发明人: Jamal TAZI , Florence MAHUTEAU , Romain NAJMAN , Didier SCHERRER , Noelie CAMPOS , Aude GARCEL
IPC分类号: C07D401/12
CPC分类号: C07D403/12 , A61K31/4709 , A61K31/4985 , C07D213/74 , C07D215/38 , C07D215/42 , C07D215/46 , C07D241/44 , C07D401/12
摘要: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R″ is a hydrogen atom or a (C1-C4)alkyl group; n′ is 1 or 2; n is 1, 2, or 3; R independently represents a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —NR1R2 group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a (C1-C3)fluoroalkoxy, and a (C1-C4)alkoxy group; R′ is a hydrogen atom, a halogen atom, or a group selected from a (C1-C3)alkyl group, a —COOR1 group, a —NO2 group, a —NR1R2 group, a (C1-C4)alkoxy group, and a CN group; R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group; with the proviso that when R and R′ are not simultaneously a hydrogen atom: when n is 1, R is not a methyl group in an ortho or para position with respect to N, when R′ is a hydrogen atom, R is not a bromine atom or a chlorine atom, and when R is a hydrogen atom, R is not a methyl or ethyl group, a —COOH group, a —COOC2H5 group, or a bromine atom that is in an ortho position of the bond linked to NR″.
摘要翻译: 具有下式的化合物或其药学上可接受的盐:其中:R“是氢原子或(C 1 -C 4)烷基; n'为1或2; n为1,2或3; R独立地表示氢原子,卤素原子或选自(C1-C3)烷基,-CN基,羟基,-NR1R2基,-COOR1基,(C1-C3) 氟烷基,-NO 2基,(C1-C3)氟烷氧基和(C1-C4)烷氧基; R'是氢原子,卤素原子或选自(C1-C3)烷基,-COOR1基,-NO2基,-NR1R2基,(C1-C4)烷氧基的基团和 CN组; R1和R2是氢原子或(C1-C3)烷基; 条件是当R和R'不同时为氢原子时:当n为1时,当R'为氢原子时,R不为相对于N的邻位或对位的甲基,R不为 溴原子或氯原子,当R为氢原子时,R不是甲基或乙基,-COOH基团,-COOC2H5基团或与NR键合的邻位的溴原子 “。
-
公开(公告)号:US20240343716A1
公开(公告)日:2024-10-17
申请号:US18435619
申请日:2024-02-07
申请人: ABIVAX , CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
发明人: Jamal TAZI , Florence MAHUTEAU , Pierre ROUX , Romain NAJMAN , Didier SCHERRER , Carsten BROCK , Nathalie CAHUZAC , Gilles GADEA , Noelie CAMPOS , Aude GARCEL , Julien SANTO
IPC分类号: C07D413/04 , A61K31/4709 , A61K31/4985 , C07D213/74 , C07D215/38 , C07D215/42 , C07D215/46 , C07D217/02 , C07D241/44 , C07D401/12 , C07D403/12
CPC分类号: C07D413/04 , A61K31/4709 , A61K31/4985 , C07D213/74 , C07D215/38 , C07D215/42 , C07D215/46 , C07D217/02 , C07D241/44 , C07D401/12 , C07D403/12
摘要: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being:
where:
R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group;
R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and
R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.-
公开(公告)号:US20150307478A1
公开(公告)日:2015-10-29
申请号:US14789250
申请日:2015-07-01
申请人: ABIVAX , CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE MONTPELLIER 2
发明人: Jamal TAZI , Florence MAHUTEAU , Romain NAJMAN , Didier SCHERRER , Noelie CAMPOS , Aude GARCEL
IPC分类号: C07D403/12 , C07D215/38 , C07D241/44 , C07D401/12
CPC分类号: C07D403/12 , A61K31/4709 , A61K31/4985 , C07D213/74 , C07D215/38 , C07D215/42 , C07D215/46 , C07D241/44 , C07D401/12
摘要: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R″ is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n′ is 1 or 2.
摘要翻译: 具有下式的化合物或其药学上可接受的盐:其中:R独立地表示氢原子,卤素原子,(C1-C3)烷基,-NR1R2基,(C1-C3)氟烷氧基, -NO 2基,苯氧基或(C1-C4)烷氧基,R1和R2独立地为氢原子或(C1-C3)烷基,R'为氢原子,卤素原子,(C1 -C 3)烷基或(C 1 -C 4)烷氧基,R“为氢原子或(C 1 -C 4)烷基,n为1,2或3,n'为1或2。
-
-
-
-
-
-
-